Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SEC.report/Document/0001554795-21-000190/ Form NT 10-Q has been filed by: Filer: PCT LTD
Notice of Late Quarterly Filing accepted on 2021-05-17 16:15:32
which breakout board? Link?
you wrote:
you wrote:
you wrote:
Will your food truck have “poor man noodles” on the menu?
you wrote:
The high share trading volume on April 30 seems to have been related to https://www.businesswire.com/news/home/20210430005359/en/PCT-LTD-Releases-Current-Oilfield-Testing-Update
Why & who bought or sold the shares ... who knows.
50% down? This is still confusing to me. Is that 50% of the sale price of Annihilyzers? If they are leasing the Annihilyzers in the UK, then how would this also involve 50% down?
you wrote:
you wrote:
you wrote:
You wrote: “At one point the company told us they intended to build 25 Annihilyzer units a month, and build more each months. We've really never heard how many they did build, or how many they could.”
Instead: I believe the company indicated “they could see a need to build 25 Annihilyzers per month”, but I get the impression they have always lacked the readily available funding to manufacture that many in a single month. However, if sufficiently large orders are received then perhaps they could tap in to market rate funding for such manufacturing.
I get the impression that most of their PR’s about orders placed or fulfilled just involved a few or a handful. I do not get the impression they had/have an inventory of a dozen Annihilyzers.
Best wishes to you DesertEagle in your business shift to Oil/Gas & perhaps AG soon too.
you wrote:
No. See for example my Post 161044.
Tweet - from PCTL
you wrote:
Re: David Holcomb, I also find this older article about nanoparticles and enhanced oil recovery interesting!
https://www.upstreamonline.com/upstreamtechnology/small-dose-big-results/2-1-219479
you wrote:
It all goes back to your post 160662, in which you wrote:
Yes, those 15 Million ("free") shares is what I was thinking of (as part of his contract).
you wrote:
you wrote:
you wrote:
you wrote:
Here is a guess:
“Breakeven” = $0.017 @ $600K Revenue Q1 (= no improvement over 2020 annual/quarterly run rate)
$0.04 at $1.25 M
$0.05 at $1.5 M
$0.06 at $1.75 M
$0.07 at $2.0 M
$0.08 at $2.25 M
$0.09 at $2.5M (= $10 M annual run rate)
New status in March 2021 ... "Recruiting" (not sure if anyone had recently posted this info?). Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma.
ClinicalTrials.gov Identifier: NCT04201873
Recruitment Status : Recruiting
First Posted : December 17, 2019
Last Update Posted : March 12, 2021
Brief Summary:
This phase I trial studies the side effects and how well of pembrolizumab and a vaccine therapy (ATL-DC vaccine) work in treating patients with glioblastoma that has come back (recurrent) and can be removed by surgery (surgically accessible). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vaccines, such as ATL-DC vaccine, may help the body build an effective immune response to kill tumor cells. Giving pembrolizumab and ATL-DC vaccine may work better in treating patients with glioblastoma compared to ATL-DC alone.
Condition or disease Intervention/treatment Phase
Recurrent Glioblastoma
Biological: Dendritic Cell Tumor Cell Lysate Vaccine
Biological: Pembrolizumab
Other: Placebo Administration
Drug: Poly ICLC
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase I Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Antibody Pembrolizumab With Autologous Tumor Lysate-Pulsed Dendritic Cell Vaccination in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Actual Study Start Date : January 8, 2020
Estimated Primary Completion Date : August 1, 2024
Estimated Study Completion Date : August 1, 2025
Contacts
Contact: Sichen Li 626 921-4291 SichenLi@mednet.ucla.edu
Contact: Stacey Green 310 825-5321 SDGreen@mednet.ucla.edu
Locations
United States, California
UCLA / Jonsson Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90095
Contact: Stacey Green 310-825-5321 SDGreen@mednet.ucla.edu
Contact: Sichen Li 626 921-4291 SDGreen@mednet.ucla.edu
Principal Investigator: Timothy F. Cloughesy
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Merck Sharp & Dohme Corp.
Phase One Foundation
Oncovir, Inc.
Investigators
Principal Investigator: Timothy F Cloughesy UCLA / Jonsson Comprehensive Cancer Center
https://clinicaltrials.gov/ct2/show/NCT04201873
I must have missed something. What are you referring to regarding some “new company”?
New Tweet today:
you wrote:
you wrote:
you wrote:
you wrote:
Your speculation of diving into the close was incorrect.
you wrote:
you wrote:
you wrote:
,you wrote: 'beachhyena' If you want to become a US citizen real quick. Just go to Mexico, join the herds of illegal 's crossing the boarder ,and you will get your citizenship a hellava lot quicker than going the legal route.
Would that be an illegal coyote-assisted Mexican desert beachhyena crossing?
you wrote: